LAUNXP BIOMEDICAL CO., LTD.(TW:6876)
NT$14.05+0.05 (+0.36%)
TW:6876
LAUNXP BIOMEDICAL CO., LTD. financials statements
NT$14.05
At close:+0.05 (+0.36%)
LAUNXP BIOMEDICAL CO., LTD. (6876) Ratios
LAUNXP BIOMEDICAL CO., LTD. Ratios
TW:6876's free cash flow for Q2 2026 was NT$-75.32M. For the 2026 fiscal year, TW:6876's free cash flow was decreased by NT$-333.00K and operating cash flow was NT$-74.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.68 | 7.53 | 8.63 | 3.20 | 12.42 |
| Quick Ratio | 0.68 | 7.53 | 8.63 | 3.20 | 12.42 |
| Cash Ratio | 0.36 | 7.06 | 8.36 | 2.01 | 6.60 |
| Solvency Ratio | -0.71 | -5.33 | -3.39 | -4.03 | -3.83 |
| Operating Cash Flow Ratio | -0.98 | -5.50 | -2.75 | -5.83 | -5.61 |
| Short-Term Operating Cash Flow Coverage | -20.67 | -678.39 | 0.00 | 0.00 | -37.90 |
| Net Current Asset Value | NT$ -56.99M | NT$ 89.88M | NT$ 162.32M | NT$ 14.02M | NT$ 55.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.02 | 0.01 | 0.11 | 0.07 |
| Debt-to-Equity Ratio | 0.08 | 0.02 | 0.01 | 0.16 | 0.08 |
| Debt-to-Capital Ratio | 0.07 | 0.02 | 0.01 | 0.14 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.60 | 1.14 | 1.13 | 1.46 | 1.13 |
| Debt Service Coverage Ratio | -15.21 | -517.11 | -469.27 | -210.60 | -40.10 |
| Interest Coverage Ratio | -186.12 | -1959.62 | -485.32 | -222.65 | -578.10 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.51 | 0.10 | 0.12 | 0.21 | 0.31 |
| Net Debt to EBITDA | 0.28 | 1.20 | 2.26 | 0.28 | 0.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 91.99% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | -3303.10% | -734381.82% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | -3206.44% | -712436.36% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | -3313.37% | -736809.09% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -3304.79% | -735900.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | -3325.08% | -735900.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -3325.08% | -735900.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.61% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.17% | 99.74% | 99.88% | 100.45% | 100.18% |
| Return on Assets (ROA) | -27.30% | -66.66% | -39.20% | -134.43% | -47.03% |
| Return on Equity (ROE) | -43.72% | -75.87% | -44.16% | -196.34% | -53.27% |
| Return on Capital Employed (ROCE) | -41.91% | -74.84% | -43.81% | -174.63% | -50.49% |
| Return on Invested Capital (ROIC) | -40.90% | -73.97% | -43.59% | -168.39% | -49.29% |
| Return on Tangible Assets | -104.40% | -75.91% | -42.41% | -141.18% | -48.11% |
| Earnings Yield | -11.81% | -16.60% | -15.36% | -10.80% | -9.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.71 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4372.66 | 2953.18 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 2953.18 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 4372.66 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 2953.18 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.41 | -3.26 | -2.51 | -2.45 | -1.72 |
| Free Cash Flow Per Share | -3.46 | -3.27 | -2.65 | -2.50 | -1.97 |
| Dividend Paid and CapEx Coverage Ratio | -71.57 | -242.59 | -17.84 | -54.99 | -6.83 |
| Capital Expenditure Coverage Ratio | -71.57 | -242.59 | -17.84 | -54.99 | -6.83 |
| Operating Cash Flow Coverage Ratio | -6.90 | -31.82 | -22.33 | -12.38 | -5.64 |
| Operating Cash Flow to Sales Ratio | 0.00 | -30.86 | -5376.09 | 0.00 | 0.00 |
| Free Cash Flow Yield | -14.70% | -15.47% | -11.85% | -11.15% | -8.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.47 | -6.03 | -6.51 | -9.26 | -10.87 |
| Price-to-Sales (P/S) Ratio | 0.00 | 200.36 | 47919.07 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.70 | 4.57 | 2.88 | 18.17 | 5.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.81 | -6.47 | -8.44 | -8.97 | -11.37 |
| Price-to-Operating Cash Flow Ratio | -6.90 | -6.49 | -8.91 | -9.13 | -13.03 |
| Price-to-Earnings Growth (PEG) Ratio | 0.41 | -2.96 | -0.15 | -0.53 | 0.48 |
| Enterprise Value Multiple | -8.31 | -5.04 | -4.47 | -9.55 | -10.55 |
| Enterprise Value | 900.90M | 401.73M | 350.02M | 392.05M | 348.85M |
| EV to EBITDA | -8.31 | -5.04 | -4.47 | -9.55 | -10.55 |
| EV to Sales | 0.00 | 161.73 | 31820.34 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.58 | -5.22 | -5.60 | -8.71 | -10.50 |
| EV to Operating Cash Flow | -6.67 | -5.24 | -5.92 | -8.87 | -12.03 |
| Tangible Book Value Per Share | -1.16 | 3.98 | 7.13 | 1.15 | 3.77 |
| Shareholders’ Equity Per Share | 6.36 | 4.63 | 7.79 | 1.23 | 3.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.78 | -3.51 | -3.44 | -2.42 | -2.06 |
| Tax Burden | 1.00 | 1.01 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 15.16 | 3970.55 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 18.90 | 3398.55 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 1.89 | 479.73 | 0.00 | 0.00 |
| Income Quality | 1.23 | 0.93 | 0.73 | 1.01 | 0.83 |
Currency in TWD
